Fall Clinical 2025 News: Denifanstat Hits All Endpoints in Phase 3 Acne Trial
Denifanstat met all primary and secondary endpoints and was well-tolerated in moderate-to-severe acne vulgaris, according to a Phase 3 clinical trial in acne in China.
Category: Conference Bytes